NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

MYGN

Myriad Genetics, Inc

Jun 30 • 04:00PM ET

5.31

Dollar change +0.06
Percentage change 1.14	%

Healthcare • Diagnostics & Research • USA • NASD

Peers: ILMN GH INCY QGEN EXAS NTLA CRSP CDNA TXG TWST

| Held by: IJR IWM VTI VB XBI VXF VBR IJS IWN SPSM

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.12	Insider Own	5.19%	Shs Outstand	92.20M	Perf Week	9.26%
Market Cap	489.46M	Forward P/E	34.64	EPS next Y	0.15	Insider Trans	0.00%	Shs Float	87.40M	Perf Month	27.64%
Enterprise Value	555.26M	PEG	-	EPS next Q	-0.01	Inst Own	102.41%	Short Float	9.59%	Perf Quarter	-40.20%
Income	-101.40M	P/S	0.59	EPS this Y	-106.08%	Inst Trans	1.50%	Short Ratio	3.71	Perf Half Y	-61.35%
Sales	831.30M	P/B	0.69	EPS next Y	1899.78%	ROA	-9.58%	Short Interest	8.38M	Perf YTD	-61.27%
Book/sh	7.65	P/C	5.33	EPS next 5Y	24.07%	ROE	-13.84%	52W High	29.30 -81.88%	Perf Year	-78.43%
Cash/sh	1.00	P/FCF	-	EPS past 3/5Y	-59.13% -	ROIC	-11.91%	52W Low	3.81 39.30%	Perf 3Y	-71.90%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	6.64% -0.32%	Gross Margin	67.47%	Volatility	4.89% 6.13%	Perf 5Y	-56.69%
Dividend TTM	-	EV/Sales	0.67	EPS Y/Y TTM	60.45%	Oper. Margin	-10.72%	ATR (14)	0.31	Perf 10Y	-84.69%
Dividend Ex-Date	-	Quick Ratio	1.71	Sales Y/Y TTM	7.38%	Profit Margin	-12.20%	RSI (14)	54.37	Recom	3.12
Dividend Gr. 3/5Y	- -	Current Ratio	1.90	EPS Q/Q	99.62%	SMA20	4.87%	Beta	1.90	Target Price	7.36
Payout	-	Debt/Eq	0.22	Sales Q/Q	-3.12%	SMA50	-0.87%	Rel Volume	0.40	Prev Close	5.25
Employees	2700	LT Debt/Eq	0.21	Earnings	May 06 AMC	SMA200	-59.90%	Avg Volume	2.26M	Price	5.31
IPO	Oct 06, 1995	Option/Short	Yes / Yes	EPS/Sales Surpr.	44.95% -2.32%	Trades		Volume	907,164	Change	1.14%

Date	Action	Analyst	Rating Change	Price Target Change
May-21-25	Downgrade	Scotiabank	Sector Outperform → Sector Perform	$6
May-08-25	Downgrade	Wolfe Research	Outperform → Peer Perform
May-07-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$6
Apr-09-25	Downgrade	Guggenheim	Buy → Neutral
Mar-12-25	Upgrade	Piper Sandler	Neutral → Overweight	$11.50 → $12.50
Feb-12-25	Initiated	Craig Hallum	Buy	$29
Dec-10-24	Initiated	UBS	Neutral	$18
Dec-09-24	Downgrade	Leerink Partners	Outperform → Market Perform	$30 → $21
Sep-19-24	Initiated	Morgan Stanley	Equal-Weight	$32
Aug-28-24	Initiated	Wells Fargo	Overweight	$35
Jun-27-24	Initiated	Scotiabank	Sector Outperform	$29
Jun-03-24	Resumed	Jefferies	Underperform	$20
May-08-24	Upgrade	Leerink Partners	Market Perform → Outperform	$25 → $35
Dec-21-23	Resumed	Piper Sandler	Neutral	$23
Dec-19-23	Initiated	Wells Fargo	Equal Weight	$20
Dec-14-23	Initiated	Guggenheim	Buy	$23
Dec-13-23	Initiated	Wolfe Research	Outperform	$28
Jul-05-23	Resumed	JP Morgan	Underweight	$18
May-23-23	Upgrade	Goldman	Sell → Buy	$18 → $25
Jan-18-23	Upgrade	Raymond James	Mkt Perform → Outperform	$25

Show Previous Ratings

Jun-27-25 05:22AM	5 Revealing Analyst Questions From Myriad Genetics's Q1 Earnings Call (StockStory)
Jun-16-25 08:25AM	Should You Hold Myriad Genetics Stock in Your Portfolio Right Now? (Zacks)
Jun-06-25 09:09AM	Tempus AI Eyes Positive Adjusted EBITDA in 2025: Is It Taking Shape? (Zacks)
12:01AM	3 Reasons to Avoid MYGN and 1 Stock to Buy Instead (StockStory)
Jun-05-25 11:31AM	Myriad (MYGN) Up 23.9% Since Last Earnings Report: Can It Continue? (Zacks) -6.99%
09:00AM	Loading…
Jun-03-25 09:00AM	Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen (GlobeNewswire) +9.42%
Jun-02-25 09:00AM	Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types (GlobeNewswire) +6.44%
May-27-25 07:53PM	Myriad Genetics, Inc. (MYGN) Showcases Breakthrough MRD Data and AI-Driven Cancer Tools at ASCO 2025 (Insider Monkey) +6.14%
04:05PM	Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting (GlobeNewswire)
May-26-25 11:34PM	Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1 (StockStory)
May-19-25 09:58AM	MYGN Q1 Earnings Call: Guidance Cut Amid GeneSight Challenges and Slow Hereditary Cancer Ramp (StockStory) +7.26%
May-14-25 04:45PM	Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences (GlobeNewswire) -6.57% +7.03%
May-09-25 04:07AM	Myriad Genetics, Inc. (MYGN): Among Billionaire Larry Robbins' Stock Picks with Huge Upside Potential (Insider Monkey)
May-08-25 09:35AM	Down -49.47% in 4 Weeks, Here's Why Myriad (MYGN) Looks Ripe for a Turnaround (Zacks) -5.62%
May-07-25 04:30PM	Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology (GlobeNewswire) -41.27%
08:34AM	Loading…
08:34AM	MYGN Q1 Earnings Top Estimates, Stock Down on Weak 2025 Outlook (Zacks)
03:19AM	Myriad Genetics Inc (MYGN) Q1 2025 Earnings Call Highlights: Navigating Revenue Challenges and ... (GuruFocus.com)
May-06-25 11:35PM	Myriad genetics lowers 2025 revenue guidance by $35M amid GeneSight challenges (Seeking Alpha) -5.58%
11:35PM	Myriad Genetics, Inc. (MYGN) Q1 2025 Earnings Call Transcript (Seeking Alpha)
07:30PM	Myriad (MYGN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:35PM	Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance (GlobeNewswire)
May-02-25 12:58AM	Myriad Genetics: Significantly Undervalued With Profitability In Sight (Seeking Alpha) +6.03%
12:39AM	3 Unprofitable Stocks Walking a Fine Line (StockStory)
May-01-25 12:34AM	1 Unprofitable Stock to Target This Week and 2 to Be Wary Of (StockStory)
Apr-30-25 08:00AM	Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor (GlobeNewswire)
Apr-29-25 09:00AM	Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025 (GlobeNewswire)
Apr-25-25 04:05PM	Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting (GlobeNewswire)
09:16AM	3 Healthcare Stocks That Concern Us (StockStory)
Apr-22-25 10:10AM	Hologic vs. MYGN: Which Molecular Diagnostics Player Has More Upside? (Zacks)
04:05PM	Loading…
Apr-21-25 04:05PM	Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing (GlobeNewswire)
Apr-15-25 10:02AM	Myriad Genetics price target lowered to $9 from $11 at BofA (TipRanks)
Apr-08-25 04:15PM	Myriad Genetics Announces Inducement Awards (GlobeNewswire) +9.31%
Apr-07-25 08:00AM	Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer (GlobeNewswire)
Mar-28-25 08:56AM	Is Myriad Genetics Stock Worth Holding in Your Portfolio Now? (Zacks)
Mar-26-25 11:30AM	Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound? (Zacks) -5.34%
Mar-25-25 10:45AM	Allspring Small Company Growth Fund Q4 2024 Commentary (SeekingAlpha)
Mar-21-25 08:30AM	Artisan International Small-Mid Fund Q4 2024 Commentary (SeekingAlpha)
Mar-19-25 05:05AM	A Look Back at Therapeutics Stocks Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack (StockStory)
Mar-17-25 05:10AM	Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q4 Earnings? (StockStory)
Mar-12-25 01:17PM	Why Are Myriad Genetics (MYGN) Shares Soaring Today (StockStory)
Mar-11-25 05:03AM	Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks (StockStory) +6.77%
Mar-04-25 04:03AM	Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4 (StockStory)
Feb-27-25 04:15PM	Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools (GlobeNewswire)
Feb-25-25 02:07PM	Why Myriad Genetics (MYGN) Shares Are Plunging Today (StockStory) -14.80%
10:25AM	Myriad Genetics, Inc. (MYGN): AI-Driven Precision Medicine for Prostate Cancer (Insider Monkey)
07:59AM	Q4 2024 Myriad Genetics Inc Earnings Call (Thomson Reuters StreetEvents)
02:03AM	Myriad Genetics Inc (MYGN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Feb-24-25 07:00PM	Myriad (MYGN) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
06:00PM	Myriad Genetics (MYGN) Meets Q4 Earnings Estimates (Zacks)
05:11PM	Myriad: Q4 Earnings Snapshot (Associated Press Finance)
04:31PM	Myriad Genetics (NASDAQ:MYGN) Misses Q4 Sales Targets, Stock Drops (StockStory)
04:05PM	Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth (GlobeNewswire)
04:05PM	Myriad Genetics Announces Senior Leadership Transition (GlobeNewswire)
08:30AM	Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio (GlobeNewswire)
Feb-23-25 08:01AM	What To Expect From Myriad Geneticss (MYGN) Q4 Earnings (StockStory)
Feb-19-25 08:30AM	Myriad Genetics Included in Forbes America's Best Employers 2025 List (GlobeNewswire)
Feb-18-25 08:30AM	Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025 (GlobeNewswire)
Feb-17-25 06:05AM	3 Reasons to Sell MYGN and 1 Stock to Buy Instead (StockStory)
Feb-06-25 08:30AM	Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test (GlobeNewswire)
Feb-05-25 04:15PM	Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay (GlobeNewswire)
08:30AM	Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration (GlobeNewswire)
Jan-29-25 08:30AM	Myriad Genetics Unveils Groundbreaking Eight Weeks' Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference (GlobeNewswire)
Jan-24-25 08:08PM	Why Is Larry Robbins Bullish on Myriad Genetics, Inc. (MYGN) Now? (Insider Monkey)
Jan-23-25 08:30AM	Myriad Genetics Introduces Online Prenatal Genetic Testing Resource (GlobeNewswire)
Jan-21-25 08:30AM	Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology (GlobeNewswire)
Jan-15-25 08:30AM	Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance (GlobeNewswire)
Jan-09-25 04:30PM	Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History (GlobeNewswire)
Jan-08-25 11:27AM	UPDATE Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
08:00AM	Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-07-25 08:00AM	MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad's molecular residual disease assay (GlobeNewswire)
Jan-06-25 08:00AM	Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report (GlobeNewswire)
Dec-19-24 04:15PM	Myriad Genetics' RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics (GlobeNewswire)
Dec-10-24 06:26PM	Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing (GlobeNewswire) -5.41%
04:05PM	Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member (GlobeNewswire)
08:00AM	Myriad Genetics' Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines (GlobeNewswire)
Dec-09-24 04:05PM	Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium (GlobeNewswire)
08:00AM	NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris Test as an 'Advanced Tool' Recommended for Prognostic Assessment (GlobeNewswire)
Nov-20-24 04:30PM	Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina's Updated Comprehensive Gene Panel Assay, TruSight Oncology 500 v2 (GlobeNewswire)
Nov-19-24 08:00AM	Myriad Genetics Announces Prequel Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy (GlobeNewswire)
07:27AM	Myriad Genetics price target lowered to $21 from $32 at Morgan Stanley (TipRanks)
Nov-13-24 08:00AM	Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch (GlobeNewswire)
Nov-08-24 02:26AM	Myriad Genetics Inc (MYGN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Policy ... (GuruFocus.com)
Nov-07-24 06:30PM	Compared to Estimates, Myriad (MYGN) Q3 Earnings: A Look at Key Metrics (Zacks)
06:00PM	Myriad Genetics (MYGN) Q3 Earnings and Revenues Surpass Estimates (Zacks)
05:02PM	Myriad: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance (GlobeNewswire)
Nov-04-24 08:39AM	Myriad Genetics Comments on UnitedHealthcare's Updated Medical Policy for Pharmacogenetic Testing (GlobeNewswire)
Nov-02-24 11:15AM	Myriad weakness due to UnitedHealth coverage update, says Stephens (TipRanks)
Nov-01-24 06:55PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research) -18.08%
Oct-30-24 08:00AM	Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024 (GlobeNewswire)
Oct-28-24 10:01AM	Myriad Genetics (MYGN) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-22-24 02:19PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research)
Oct-16-24 09:00AM	Myriad Genetics and jscreen Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access (GlobeNewswire)
Oct-15-24 09:00AM	Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration (GlobeNewswire)
Oct-09-24 07:49AM	Myriad signs five partnerships to study MRD testing in breast cancer (Clinical Trials Arena) -6.12%
Oct-08-24 04:05PM	Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer (GlobeNewswire)
Oct-04-24 06:33AM	Myriad and Ultima to study UG 100 sequencing platform for genomics clinical tests (Medical Device Network)
Oct-03-24 09:00AM	Myriad Genetics and Ultima Genomics to Explore the UG 100 Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics (GlobeNewswire)
Oct-01-24 04:05PM	Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date (GlobeNewswire)

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DIAZ PAUL J	President and CEO	Oct 11 '24	Sale	22.93	15,000	343,950	962,378	Oct 11 05:23 PM
DIAZ PAUL J	Officer	Oct 11 '24	Proposed Sale	22.93	15,000	343,950		Oct 11 10:35 AM
Ancona Margaret	Officer	Aug 21 '24	Proposed Sale	27.82	11,538	321,019		Sep 16 02:30 PM
DIAZ PAUL J	President and CEO	Sep 11 '24	Sale	26.72	15,000	400,800	977,378	Sep 12 04:11 PM
Muzzey Dale	Chief Scientific Officer	Sep 11 '24	Sale	26.17	2,100	54,961	108,013	Sep 12 04:09 PM
Muzzey Dale	Officer	Sep 11 '24	Proposed Sale	26.17	2,100	54,961		Sep 11 03:26 PM
DIAZ PAUL J	Officer	Sep 11 '24	Proposed Sale	26.72	15,000	400,800		Sep 11 10:05 AM
Dreismann Heinrich	Director	Sep 09 '24	Sale	27.05	10,000	270,520	121,648	Sep 09 05:48 PM
Dreismann Heinrich	Director	Sep 10 '24	Proposed Sale	27.00	10,000	270,000		Sep 09 02:52 PM
Reitan Colleen F	Director	Sep 03 '24	Sale	27.95	46,012	1,285,851	42,533	Sep 04 07:38 PM
Reitan Colleen F	Director	Sep 03 '24	Proposed Sale	28.19	46,012	1,297,078		Sep 03 10:11 AM
Ancona Margaret	SVP, Chief of Staff	Aug 21 '24	Sale	27.82	11,538	320,987	79,366	Aug 23 04:16 PM
Kumar Rashmi	Director	Aug 19 '24	Sale	28.01	7,500	210,075	77,392	Aug 20 04:38 PM
Kumar Rashmi	Director	Aug 19 '24	Proposed Sale	28.01	7,500	210,075		Aug 19 02:46 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MYGN

Myriad Genetics, Inc

Upgrade your FINVIZ experience